Clinical Trial Update: ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ABI-007 in persistent or recurrent cervical cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Cervical Cancer
• Cervical Carcinoma
• Cervical Small Cell Carcinoma
• Cervical Squamous Cell Carcinoma

Drugs mentioned

• ABI-007 (nab-paclitaxel)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-08